Biogen Inc Stock Price Increases 4.03% on July 1

Biogen Inc, a healthcare biotechnology company, reported a 4.03% increase in its stock price on July 1.

The company’s stock price surge is attributed to the initiation of a Phase 3 study for its treatment, felzartamab, which targets primary membranous nephropathy, a rare immune-mediated disease affecting the kidneys.

Study Details

• The Phase 3 study aims to evaluate the efficacy and safety of felzartamab compared to tacrolimus.
• The study will provide critical data on the treatment’s effectiveness and potential side effects.

Market Performance

The broader market experienced losses on July 1, with the NASDAQ 100 index declining by 0.89%.

Key Statistics

• Biogen Inc stock price increase: 4.03% on July 1
• NASDAQ 100 index decline: 0.89% on July 1